---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-024168"
form_type: "8-K"
ticker: "SEER"
cik: "0001726445"
company_name: "Seer, Inc."
filed_at: "2021-11-29T23:59:59+00:00"
generated_at: "2026-06-28T05:09:05.891161+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Seer appoints Meeta Gulyani to Board of Directors; brings life sciences industry experience from Merck KGaA

## Summary
- Appointed Meeta Gulyani as Class III director with term expiring at 2023 annual meeting.
- Gulyani is EVP, Head of Strategy, Business Development & Transformation for Merck KGaA's Life Science business (MilliporeSigma).
- Received initial stock option for 30,000 shares vesting monthly over 3 years; annual cash retainer of $40,000.
- Board expanded from nine to ten directors effective November 29, 2021.

## SEC filing metadata
- accession: 0001628280-21-024168
- form_type: 8-K
- ticker: SEER
- cik: 0001726445
- company_name: Seer, Inc.
- filed_at: 2021-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726445/000162828021024168/0001628280-21-024168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726445/000162828021024168/seer-20211129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-024168
- JSON: https://secwatch.observer/filing/0001628280-21-024168.json
- Plain text: https://secwatch.observer/filing/0001628280-21-024168.txt

## Key facts
- Executive change
  Meeta Gulyani was appointed as Director at Seer, Inc..
  - Action: appointed
  - Role: Director
  source text: Contemporaneously, Meeta Gulyani was appointed to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726445/000162828021024168/0001628280-21-024168-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.